Pharma BD Deal Intelligence
Sanofi's $500M upfront gamble on Teva's duvakitug looks like an early win: the Phase 2b RELIEVE UCCD study hit its primary endpoints in both ulcerative colitis and Crohn's disease, though the $1.5B collaboration still needs Phase 3 to confirm best-in-class claims.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi is the latest large drugmaker to place a bet on TL1A, one of the hottest targets in inflammatory bowel disease. The French pharma agreed to pay Teva…
France's Sanofi and Israel's Teva said on Wednesday they had signed a co-development and co-commercialization agreement worth up to $1.5 billion for Teva's…
Sanofi and Teva's duvakitug Phase 2b maintenance (week 44) data demonstrated clinically meaningful durable efficacy: ulcerative colitis clinical remission…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Sanofi and Teva entered a global co-development and co-commercialization collaboration for duvakitug (TEV'574 / TEV-48574), a then-Phase 2b anti-TL1A monoclonal antibody for IBD, announced October 4, 2023 (closed November 30, 2023). Teva received $500M upfront and is eligible for up to $1.0B in development/launch milestones, with equal cost/profit share in major markets and royalties elsewhere; Sanofi leads Phase 3 and commercializes in North America, Japan and most of the world while Teva commercializes in Europe, Israel and select markets. The bet has so far been validated: on December 17, 2024 the Phase 2b RELIEVE UCCD basket study met its primary endpoints in both ulcerative colitis (47.8% high-dose clinical remission vs 20.45% placebo at week 14) and Crohn's disease (47.8% high-dose endoscopic response vs 13.0% placebo), with the partners claiming best-in-class potential and a clean safety profile. Durable maintenance (week 44) data reported at ECCO 2025 and on February 17, 2026 reinforced the profile. Sanofi initiated the Phase 3 program in IBD in late 2025 (induction study NCT07184996 and maintenance study NCT07185009, both recruiting; induction actual start October 8, 2025).
3.1M US cases/yr · $25.0B Global IBD biologics / advanced-therapy market 2023 ($USD MM) · 1500 Total Sanofi-Teva deal size ($500M upfront + up to $1.0B milestones, USD MM)
Inflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn's disease (CD), is a chronic relapsing immune-mediated gastrointestinal disorder affecting approximately 3.1 million US adults per the 2015 CDC National Health Interview Survey, with modern prevalence estimates closer to 3.5-3.9 million when updated with EPI MAP modeling (Crohn's & Colitis Foundation 2023). Incidence is rising fastest in pediatric and young-adult populations, driving lifetime cost. Despite approved biologics including anti-TNFs (infliximab, adalimumab), IL-12/23 and IL-23 inhibitors (ustekinumab, risankizumab, mirikizumab), integrin inhibitors (vedolizumab), S1P modulators (ozanimod, etrasimod) and JAK inhibitors (tofacitinib, upadacitinib), only 30-40% of patients achieve durable steroid-free clinical remission and loss-of-response is common within 12-24 months. The TL1A (TNF-like ligand 1A / TNFSF15) pathway emerged as the most contested new mechanism of 2023-2024 after positive Phase 2 readouts for multiple assets demonstrated a differentiated fibrosis-modifying profile on top of inflammation control. Analyst peak-sales estimates for the TL1A class in IBD range $5-10B by 2032, driving Sanofi's $1.5B co-development with Teva, Merck's $10.8B Prometheus acquisition earlier in 2023, and Roivant/Pfizer's RVT-3101 program.
The TL1A IBD class is the most competitive new mechanism in gastroenterology, attracting more than $20B of aggregate BD capital in 2023 alone. Lead anti-TL1A programs: TEV'574 / duvakitug (Sanofi/Teva, Phase 3 in UC and CD after positive Phase 2b RELIEVE UC-CD readouts November 2024); tulisokibart / MK-7240 / PRA023 (Merck, acquired via $10.8B Prometheus Biosciences deal April 2023, Phase 3 ARTEMIS-UC / ATLAS-CD initiated 2024); RVT-3101 / afimkibart (Roivant/Pfizer, $7.5B Pfizer option exercise October 2023 through the Telavant entity, Phase 3 TRIBUTE). Adjacent mechanisms actively competing in biologics-naive and biologics-experienced settings: IL-23 inhibitors (Skyrizi / risankizumab [AbbVie, approved UC + CD], Omvoh / mirikizumab [Lilly, approved UC 2023 and CD 2024], Tremfya / guselkumab [J&J, approved UC 2024 and CD 2025]); S1P modulators (Zeposia / ozanimod [BMS, approved UC 2021], Velsipity / etrasimod [Pfizer, approved UC October 2023]); JAK inhibitors (Rinvoq / upadacitinib [AbbVie, UC and CD], Xeljanz / tofacitinib [Pfizer, UC]); anti-integrin (Entyvio / vedolizumab [Takeda]); IL-12/23 p40 (Stelara / ustekinumab [J&J, biosimilars 2024]); and anti-TNFs (Remicade / infliximab, Humira / adalimumab, Simponi / golimumab) remain the backbone. Differentiation for TL1A rests on anti-fibrotic signal, combinability with existing biologics, and steroid-free remission rates that have outperformed historical IL-23 benchmarks in Phase 2. Sanofi's deal gives it a first-in-class late-stage biologic to refresh its GI franchise beyond Dupixent.
Duvakitug met both Phase 2b primary endpoints: UC clinical remission 47.8% (high dose) vs 20.45% placebo; CD endoscopic response 47.8% vs 13.0% placebo at week 14. Best-in-class claim; clean safety profile.
Sanofi-sponsored Phase 3 program in IBD underway. Induction study NCT07184996 (RECRUITING, actual start 2025-10-08) and maintenance study NCT07185009.
Week-44 maintenance data: UC clinical remission 58% (900 mg) / 47% (450 mg); CD endoscopic response 55% (900 mg) / 41% (450 mg). Reinforces best-in-class profile.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Teva Pharmaceutical Industries Ltd. (this deal) | 2023 | $1.5B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2023 deals · Sanofi SA deals · Gastroenterology deals